Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bard buys Californian bulking agent firm Genyx:

This article was originally published in Clinica

Executive Summary

CR Bard has agreed to buy Genyx Medical, a private firm based in Aliso Viejo, California, that makes and markets an alternative treatment to surgery for stress urinary incontinence. For an undisclosed sum, it has acquired the assets related to Uryx, a CE marked bulking agent that is injected into the area surrounding the female urethra to support the urinary sphincter. The product is in late-stage trials in the US and Genyx expects to file for pre-market approval in the first half of this year. Bard already markets a collagen implant, Contigen, to treat the condition.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060895

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel